Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings?

IQVIA Holdings Inc. (NYSE:IQV) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on IQVIA Holdings Inc. (NYSE:IQV) to $215 from $266 on February 23, reiterating an Outperform rating on the shares and updating its model on the company after the fiscal Q4 report. Truist also lowered the price target on the stock to $245 from $290 on February 19. It maintained a Buy rating on the shares, telling investors that it is updating its model on IQVIA Holdings Inc. (NYSE:IQV) after the re-segmentation following the company’s Q4 earnings, while also reducing its assumed forward EBITDA multiple to 13x from 14x to take into account the near-term AI disruption overhang.

IQVIA Holdings (IQV) Snaps 2-Day Losses on Higher-than-Expected Earnings

In another development, TD Cowen cut the price target on IQVIA Holdings Inc. (NYSE:IQV) to $174 from $245 on February 17 and maintained a Hold rating on the shares. The firm updated its model following Q4 results and guidance, stating that while it believes risks from AI exist, it is crucial to note that they will play out over the long term, and the impact on CROs isn’t fully clear.

IQVIA Holdings Inc. (NYSE:IQV) provides advanced analytics, clinical research services, and technology solutions for the life sciences industry. Its operations are divided into Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions segments.

While we acknowledge the potential of IQV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IQV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.